Patents by Inventor Guang-Tzuu Shane

Guang-Tzuu Shane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10639292
    Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and an ?-glycosidase inhibitor in the treatment of conditions and/or disorders related to hyperglycemia.
    Type: Grant
    Filed: November 3, 2018
    Date of Patent: May 5, 2020
    Assignee: CENTER LABORATORIES, INC.
    Inventors: Jui-Pao Hsu, Guang-Tzuu Shane, Meng-Ju Lee, Yi-Ping Liao, Yu-Yin Yeh, Shu-Hsien Chang
  • Publication number: 20190321326
    Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and an ?-glycosidase inhibitor in the treatment of conditions and/or disorders related to hyperglycemia.
    Type: Application
    Filed: November 3, 2018
    Publication date: October 24, 2019
    Applicant: Center Laboratories, Inc.
    Inventors: Jui-Pao HSU, Guang-Tzuu SHANE, Meng-Ju LEE, Yi-Ping LIAO, Yu-Yin YEH, Shu-Hsien CHANG
  • Publication number: 20190321327
    Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and insulin or an insulin analogue in the treatment of mellitus and/or disorders related to diabetes mellitus.
    Type: Application
    Filed: March 25, 2019
    Publication date: October 24, 2019
    Applicant: Center Laboratories, Inc.
    Inventors: Jui-Pao HSU, Guang-Tzuu SHANE, Meng-Ju LEE, Yi-Ping LIAO, Yu-Yin YEH, Shu-Hsien CHANG
  • Patent number: 10278943
    Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof in the treatment of conditions and/or disorders related to hyperglycemia.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: May 7, 2019
    Assignee: Center Laboratories, Inc.
    Inventors: Jui-Pao Hsu, Guang-Tzuu Shane, Meng-Ju Lee, Yi-Ping Liao, Yu-Yin Yeh
  • Patent number: 10144704
    Abstract: Novel crystal forms of (R)-(+)-verapamil hydrochloride are disclosed.
    Type: Grant
    Filed: March 11, 2018
    Date of Patent: December 4, 2018
    Assignee: Center Laboratories, Inc.
    Inventors: Jui-Pao Hsu, Guang-Tzuu Shane, Yu-Yin Yeh, Meng-Ju Lee
  • Publication number: 20180235921
    Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof in the treatment of conditions and/or disorders related to hyperglycemia.
    Type: Application
    Filed: April 20, 2018
    Publication date: August 23, 2018
    Applicant: Center Laboratories, Inc.
    Inventors: Jui-Pao HSU, Guang-Tzuu SHANE, Meng-Ju LEE, Yi-Ping LIAO, Yu-Yin YEH
  • Publication number: 20180194719
    Abstract: Novel crystal forms of (R)-(+)-verapamil hydrochloride are disclosed.
    Type: Application
    Filed: March 11, 2018
    Publication date: July 12, 2018
    Applicant: Center Laboratories, Inc.
    Inventors: Jui-Pao HSU, Guang-Tzuu SHANE, Yu-Yin YEH, Meng-Ju LEE
  • Patent number: 9980935
    Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof in the treatment of conditions and/or disorders related to hyperglycemia.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 29, 2018
    Inventors: Jui-Pao Hsu, Guang-Tzuu Shane, Meng-Ju Lee, Yi-Ping Liao, Yu-Yin Yeh
  • Patent number: 9950995
    Abstract: Novel crystal forms of (R)-(?)-verapamil hydrochloride are disclosed.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: April 24, 2018
    Inventors: Jui-Pao Hsu, Guang-Tzuu Shane, Yu-Yin Yeh, Meng-Ju Lee
  • Publication number: 20170333382
    Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof in the treatment of conditions and/or disorders related to hyperglycemia.
    Type: Application
    Filed: May 17, 2017
    Publication date: November 23, 2017
    Applicant: Center Laboratories, Inc.
    Inventors: Jui-Pao HSU, Guang-Tzuu SHANE, Meng-Ju LEE, Yi-Ping LIAO, Yu-Yin YEH
  • Publication number: 20170305841
    Abstract: Novel crystal forms of (R)-(?)-verapamil hydrochloride are disclosed.
    Type: Application
    Filed: July 13, 2015
    Publication date: October 26, 2017
    Applicant: Center Laboratories, Inc.
    Inventors: Jui-Pao HSU, Guang-Tzuu SHANE, Yu-Yin YEH, Meng-Ju LEE
  • Patent number: 8802143
    Abstract: Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: August 12, 2014
    Assignee: Center Laboratories, Inc.
    Inventors: Guang-Tzuu Shane, Chien-Fen Chen, Chuen-Lin Din, Hui-Ling Tsai, Pei-Chen Tsai
  • Publication number: 20130210911
    Abstract: Disclosed herein are methods and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D2L receptor. The method comprises administering a composition comprising an effective amount of verapamil and a pharmaceutically acceptable excipient to a subject, wherein the verapamil is capable of binding to at least one of a receptor selected from the group consisting of orexin receptor 1, orexin receptor 2, somatostatin receptor 2 and dopamine D2L receptor of the subject.
    Type: Application
    Filed: October 25, 2010
    Publication date: August 15, 2013
    Applicant: CENTER LABORATORIES, INC.
    Inventors: Huai-Cheng Lee, Guang-Tzuu Shane, Hsi-Chieh Wang, Rong Jin Lin
  • Publication number: 20110171302
    Abstract: Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.
    Type: Application
    Filed: March 25, 2011
    Publication date: July 14, 2011
    Applicant: Center Laboratories, Inc.
    Inventors: Guang-Tzuu SHANE, Chien-Fen Chen, Chuen-Lin Din, Hui-Ling Tsai, Pei-Chen Tsai
  • Publication number: 20080305188
    Abstract: The present invention relates to a novel composition comprising geranium oil and extracts from the roots of the plants of the genus Sophora, preferably Sophora tonkinesis. Said composition can be administered to mammalian animals undergoing cancer treatments, such as chemotherapy and radiation therapy, that would induce the side effect of bone marrow suppression. The administration can be made before, during and or after the cancer treatment.
    Type: Application
    Filed: April 3, 2003
    Publication date: December 11, 2008
    Inventors: Hsun-Lang Chang, Wu-Chang Chuang, Wei-Ying Kuo, Guang-Tzuu Shane, Hung-Sheng Chang
  • Publication number: 20080145409
    Abstract: The present invention relates to a composition and methods of administering the composition, comprising Citronellol and its analogues and derivatives, to humans and other mammalian animals with peptic ulcers induced by alcohol consumption, H. pylori infection, stress and/or intake of nonsteroidal anti-inflammatory medications.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 19, 2008
    Inventors: Min Chang Huang, Guang-Tzuu Shane, Chang-Hua Yang, Kuo-Yen Chen
  • Patent number: 7387806
    Abstract: A method of administering an herbal composition, comprising geranium oil and extracts from roots of the plants of the genus Sophora to mammalian animals undergoing cancer treatments that induce bone marrow suppression side effect, such as chemotherapy and radiation therapy. The composition can be in the form of an oil capsule, tablets, pills, and pastes and administered orally at specific dosages. The composition can also take on the form of an injection to be administered intravenously and intraperitoneally at specific dosages. The administration can be made before and or after the cancer treatment.
    Type: Grant
    Filed: November 8, 2004
    Date of Patent: June 17, 2008
    Assignee: Medigreen Biotechnology Inc.
    Inventors: Andy A. T. Fong, Guang-Tzuu Shane
  • Publication number: 20080119567
    Abstract: The present invention relates to herbal composition and methods of administering an herbal composition, comprising geranium oil and extracts from roots of the plants of the genus Sophora, particularly S. flavescenes and S. tonkinensis, to humans and other mammalian animals with gastric ulcers induced by H. pylori infection. The same composition is shown to be able to eradicate H. pylori in vitro. The invention also relates to a composition comprising citronellol and extracts from roots of Sophora plants. The present invention further relates to the use of citronellol to inhibit gastric ulcers. The invention also relates to the use of the same composition to inhibit the enzymatic activity of Na+/K+-ATPase to strengthen heart muscle contractions and prevent heart failure.
    Type: Application
    Filed: November 20, 2007
    Publication date: May 22, 2008
    Inventors: Andy A.T. Fong, Guang-Tzuu Shane, Hsun-Lang Chang, Wei-Ying Kuo
  • Publication number: 20050095306
    Abstract: The present invention relates to a method of use involving the administration of the herbal composition, comprising geranium oil and extracts from roots of the plants of the genus Sophora, to mammalian animals undergoing cancer treatments that would induce the bone marrow suppression side effect, such as chemotherapy and radiation therapy. The composition can take on the form of an oil capsule, tablets, pills, and pastes etc. to be administered orally at specific dosages. The composition can also take on the form of an injection to be administered intravenously and intraperitoneally at specific dosages. The administration can be made before and or after the cancer treatment.
    Type: Application
    Filed: November 8, 2004
    Publication date: May 5, 2005
    Inventors: Andy Fong, Guang-Tzuu Shane
  • Publication number: 20050025823
    Abstract: The present invention relates to herbal composition and methods of administering an herbal composition, comprising geranium oil and extracts from roots of the plants of the genus Sophora, particularly S. flavescenes and S. tonkinensis, to humans and other mammalian animals with gastric ulcers induced by H. pylori infection. The same composition is shown to be able to eradicate H. pylori in vitro. The invention also relates to a composition comprising citronellol and extracts from roots of Sophora plants. The present invention further relates to the use of citronellol to inhibit gastric ulcers. The invention also relates to the use of the same composition to inhibit the enzymatic activity of Na+/K+-ATPase to strengthen heart muscle contractions and prevent heart failure.
    Type: Application
    Filed: July 28, 2004
    Publication date: February 3, 2005
    Inventors: Andy Fong, Guang-Tzuu Shane